Dr. Reckamp is a Professor in Medicine, Director of the Division of Medical Oncology at Cedars-Sinai Medical Center. She received a masters degree in Clinical Investigation from the department of Biomathematics at UCLA. Due to her leadership abilities and formal training in clinical research, she has been appointed to serve as the Associate Director of Clinical Research for the Samuel Oschin Comprehensive Cancer Institute (SOCCI). She will assure the alignment of clinical research and the allocation of resources with the mission and values of Cedars-Sinai SOCCI and the institution. Dr. Reckamp's research focus is the development of novel therapies and biomarkers for lung cancer with an emphasis on targeted therapies. She is established as a leader in clinical investigation, performing hypothesis-driven translational research in thoracic oncology. Dr. Reckamp lead collaborations with researchers across disciplines, programs and institutions. She works with lung cancer researchers across the country as a part of the Lung Cancer SPORE program to lead multi-institutional trials to evaluate targeted therapy in thoracic oncology. She has developed and led clinical trials as PI in our NCI-funded U01 Phase I and N01 Phase II Consortiums. Dr. Reckamp is an active member of the Southwest Oncology Group (SWOG) and the Lung Cancer Committee. She also represented City of Hope on the National Comprehensive Cancer Network Guidelines Committee to shape treatment guidelines in thoracic malignancies from 2008 until 2020. These multi-institutional experiences provide interactions with experts across various fields of study in the basic biomedical sciences, pharmacology, biostatistics, informatics and clinical research and are invaluable to move genomic data into clinical practice. She has successfully collaborated with colleagues, in translational research in thoracic oncology. She served as mentor to junior faculty within her institution and others outside her institution.